Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$72.05M+15.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nicholas Johnson
- Sector
- Consumer Cyclical
- Industry
- Personal Products & Services
- Employees
- 380
- Beta
- 0.69
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 3.77
Financials
Revenue
$72.05M+15.3%Net Income
$-17.51M-525.7%EBITDA
$-17.84M-328.4%Free Cash Flow
$2.87MEPS (diluted)
$-1.57-561.8%Shares Outstanding (diluted)
11.18M-6.9%Operating Expenses
$69.40MCash & Debt
$172.53MReturn of Capital
$11.0KRevenue by Segment (annual)
$301.56MDividend per Share
$1.65Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $385.79M | $-18.67M | $-1.70 |
| 2024 | $602.46M | $2.09M | $0.19 |
| 2023 | $1.07B | $99.42M | $9.10 |
| 2022 | $1.60B | $143.57M | $12.82 |
| 2021 | $1.53B | $164.03M | $14.01 |
| 2020 | $934.84M | $102.86M | $8.74 |
| 2019 | $713.67M | $77.92M | $6.62 |
| 2018 | $501.00M | $55.79M | $4.67 |
| 2017 | $301.56M | $27.72M | $2.32 |
| 2016 | $274.53M | $17.84M | $1.51 |
| 2015 | $272.77M | $20.06M | $1.68 |
| 2014 | $285.29M | $13.18M | $1.04 |
| 2013 | $356.89M | $23.97M | $1.74 |
| 2012 | $356.71M | $15.88M | $1.16 |
Valuation
MEDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-82.22%Social Signal Score
Mentions (21)
- Newszacks.com·4d ago·Negative
Can Medifast's Coaching Model Complement GLP-1 Weight-Loss Drugs? MED is positioning Trilivy as a complement to GLP-1 medications, combining nutrition and coaching to support sustainable metabolic health and weight management.
View source ↗ - Newszacks.com·12d ago·Neutral
Will Medifast's Metabolic Health Institute Strengthen Its Edge? MED advances its metabolic health strategy through a new Institute, proprietary science and Trilivy's phased wellness system.
View source ↗ - Newsfool.com·19d ago·Positive
Medifast: 3 Key Takeaways for Long-Term Investors Average revenue per active coach rose 54% year over year. Medifast ended the third quarter with $172.5 million in cash.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Medifast Is Running The Same Playbook, And I Have The Same Concerns Medifast (MED) maintains a strong, cash-heavy balance sheet and trades near liquidation value, but its business model remains uninspiring amid GLP-1 disruption. Q3 2026 revenue declined 19.4% YoY to $72M, with active earning coaches down 47%, though average revenue per coach increased. Management transition and Steamboat Capital's activist involvement signal board-level changes, but the core product and MLM-style distribution re…
View source ↗ - Newszacks.com·26d ago·Negative
Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·27d ago·Neutral
What Medifast (MED) Said on Its Q3 Earnings Call Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was within its guidance range and marked a fourth consecutive quarter in which sales stabilized around the mid-$70 million range.
View source ↗ - Newszacks.com·27d ago·Negative
Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.
View source ↗ - Newszacks.com·30d ago·Neutral
Medifast Q3 Earnings on the Horizon: Key Insights for Investors MED's Q3 results are likely to face pressure from GLP-1 adoption, shrinking coach numbers and lower sales, while strategic initiatives may offer some support.
View source ↗ - Newsglobenewswire.com·38d ago·Negative
Why Is Weight Loss Different During Menopause? Common Myths Debunked Myth: Menopause weight gain is inevitable. Truth: Acceleration is not inevitable.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
5 Questions People Ask When Every Weight Loss Approach Has Failed Trilivy's™ mission is lifelong transformation through metabolic science and human connection Baltimore, MD, Oct. 13, 2026 (GLOBE NEWSWIRE) -- When every weight loss approach has failed , individuals wonder what went wrong. The answers reside in the metabolic and behavioral research, specifically in body composition science and the accountability data that explains why human support is important.
View source ↗ - Newsglobenewswire.com·45d ago·Negative
What Actually Keeps Weight Off After a Weight Loss Program Baltimore, MD, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Weight regain after initial weight loss is a recognized pattern among individuals pursuing lasting metabolic change. Trilivy™, a science-backed, coach-guided metabolic health system, points to lean mass preservation and continued support as the two factors that keep metabolic health and its results in place.
View source ↗ - Newszacks.com·47d ago·Neutral
Can Medifast's Better Client Retention Support Revenue Stabilization? MED's revenue is stabilizing as coach productivity and client retention improve, though a shrinking coach base continues to weigh on results.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Why Do You Keep Gaining Weight Back After Losing It Baltimore, MD, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Weight comes back after weight loss when the conditions that drove it were never addressed during the weight loss phase. Trilivy™, a science-backed, coach-guided comprehensive metabolic health system, points to five factors research identifies as drivers of weight regain, rooted in body composition and habit infrastructure.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook? Baltimore, MD, Oct. 01, 2026 (GLOBE NEWSWIRE) -- The signs of poor metabolic health can be difficult to analyze without a clinical framework. Trilivy™, a science-backed, coach-guided metabolic health system, points to five frequently overlooked patterns adults can recognize before noticeable weight and energy fluctuations.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Why Weight Loss Plateaus Happen: 5 Metabolic Causes Trilivy™ is designed to address the challenges of metabolic dysfunction Clients on Trilivy's Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed approaches* Baltimore, MD, Sept. 29, 2026 (GLOBE NEWSWIRE) -- A weight loss plateau is one of the most common reasons people abandon a structured weight loss effort altogether.
View source ↗ - Newszacks.com·79d ago·Neutral
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth? MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
View source ↗ - Newszacks.com·81d ago·Neutral
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report? Medifast (MED) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·88d ago·Neutral
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health? MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.
View source ↗ - Newszacks.com·88d ago·Positive
All You Need to Know About Medifast (MED) Rating Upgrade to Buy Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·102d ago·Positive
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth? MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $0.01 per share
Typical surprise +56.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Oct 26$-0.19 vs $-0.35beat
- Mon, Aug 3$-0.28 vs $-0.65beat
- Mon, May 4$-0.19 vs $-0.55beat
- Tue, Feb 17$-0.55 vs $-0.76beat
- Mon, Nov 3$-0.21 vs $-0.01miss
- Mon, Aug 4$0.23 vs $-0.19beat
Estimates and results for MED via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MED officers and directors.
- Bought
- $2.9m
- Sold
- $278k
19 trades
3 trades
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Kiai Parsabought
- Chard Daniel Rsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (363d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
